Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 3 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Head & Neck 2Gastrointestinal 2Breast 2Sarcoma 1Lymphoid 1

Conditions

Carcinoma, Hepatocellular 2

Interventions

Oxaliplatin 780Fluorouracil 638Capecitabine 575Gemcitabine 478Leucovorin 459Bevacizumab 445Irinotecan 444Cisplatin 338Radiotherapy 283Cetuximab 252Paclitaxel 180S 1 (combination) 176pembrolizumab 173Docetaxel 156Drug Therapy 147Nivolumab 146sintilimab 143tislelizumab 131apatinib 131130-nm albumin-bound paclitaxel 128Folfox protocol 121durvalumab 119Albumin-Bound Paclitaxel 117camrelizumab 107lenvatinib 106Panitumumab 106regorafenib 102Surgical Procedures, Operative 102Sorafenib 99Radiation 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Pravastatin × Gastrointestinal × Clear all
NCT03219372 2021-01-22

Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence

Cedars-Sinai Medical Center

Phase 2 Terminated
1 enrolled 5 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT01357486 2017-05-01

PRODIGE 21

University Hospital, Bordeaux

Phase 2 Completed
160 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡